N
Novocuff
Medical device company dedicated to improving pregnancy outcomes and reducing preterm births caused by PPROM and cervical shortening
About Novocuff
Novocuff, Inc. is a medical device company established in 2021, operating out of Mountain View, California. The company is focused on the women's health sector, specifically on improving pregnancy outcomes.
Read full description
Its primary product is a medical device designed to address the issue of preterm births, particularly those caused by Preterm Premature Rupture of Membranes (PPROM) and cervical shortening. The device is intended to delay labor, thereby reducing the risks associated with premature delivery. The company targets healthcare providers and hospitals as its primary clients within the medical technology market.
Novocuff operates on a business model centered around the development and sale of this specialized medical device. The company has successfully secured significant funding, including an oversubscribed $26 million Series A round, indicating strong investor confidence in its technology and market potential. This capital is aimed at furthering product development, conducting clinical trials, and moving towards commercialization.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- San Luis Obispo, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 79.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Pregnancy, Women's Health, Femtech, Sustainable Development Goals, Woman Founder, DT and LS, science-based
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning Novocuff.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2024 | $26M | $104M | RH Capital · AXA Investment Managers · Avestria Ventures · March of Dimes | ↗ |
| SEEDEquity / VC | Jan 2022 | $2M | $8M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Novocuff is 1.4K monthly website visits, down 36.4% over the last three months. Novocuff's team grew 37.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
AXA Investment Managers
RH Capital
Avestria Ventures
March of Dimes- LFLaerdal million lives fund
Laborie
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Novocuff on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Novocuff’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.